Transthyretin Amyloid Cardiomyopathy Treatment Market is driven by...

added article Other

2024-02-29 11:38:44 -

Transthyretin Amyloid Cardiomyopathy Treatment Market is driven by Increasing Prevalence of ATTR-CM Disease

The global transthyretin amyloid cardiomyopathy treatment market is primarily driven by the increasing prevalence of ATTR-CM disease globally. Transthyretin amyloid cardiomyopathy, also known as ATTR-CM, is a rare, progressive, and frequently life-threatening heart disease caused by abnormal deposits of amyloid protein consisting of misfolded transthyretin (TTR) in the heart. ATTR-CM treatment...

0 Comments 0 Shares 477 Views 0 Reviews